## CRM: Salesforce, Inc. - XLK: Technology

### Executive Summary

VALUE thesis: PEG 1.24 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (34% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($253.94)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Salesforce (CRM) Stock Today: Weekend Headlines, Analyst Price Targets, and What to Watch Before Monday’s Market Open**
- Source: ts2.tech | 20251228T191312 | Somewhat-Bullish | Relevance: 100%
- Salesforce (CRM) is entering the final trading days of 2025 with a mix of bullish long-term analyst price targets and questions about converting its AI momentum into revenue. Recent headlines focus on institutional positioning shifts, new forecast write-ups, and the company's emphasis on AI reliability. Investors are keenly watching how macro factors, sector flows, AI sentiment, and the company's ability to translate Agentforce adoption into revenue acceleration will impact CRM stock as 2026 begins.

**2. Jim Cramer Says He Is "Not Quite Ready Yet to Give Up on Some of These Companies Like Salesforce"**
- Source: Finviz | 20251228T163143 | Bullish | Relevance: 100%
- Jim Cramer discussed Salesforce (NYSE: CRM) and its potential in the AI space, noting that despite fears of customers developing their own software, he's "not quite ready yet to give up" on the company. He highlighted the success of Salesforce's Agentforce AI platform, which has already hit a $500 million run rate and could redefine the company. Cramer was bullish on the company's latest quarterly performance, emphasizing the transformative potential of Agentforce for customer service.

**3. Novartis Selects ​Salesforce's (CRM) Agentforce Life Sciences for Customer Engagement**
- Source: Finviz | 20251228T105800 | Bullish | Relevance: 100%
- Novartis has chosen Salesforce's Agentforce Life Sciences for Customer Engagement to enhance patient and healthcare professional interactions, building on previous investments in Salesforce products. This strategic move aims to unify engagement across various teams, with a global deployment plan spanning five years. Wall Street analysts are bullish on Salesforce, citing its re-architected platform and predicted double-digit subscription revenue growth.

**4. Salesforce (CRM) Stock Update: Shares Hold Near $266 Into the Weekend as AI Forecasts, Analyst Targets, and Year-End Trading Set the Tone**
- Source: ts2.tech | 20251228T054155 | Somewhat-Bullish | Relevance: 100%
- Salesforce (NYSE: CRM) shares closed Friday at $266.08, heading into a quiet weekend amidst low trading volumes typical of the post-holiday period. The company's stock is primarily influenced by its AI monetization strategy, particularly the performance of Agentforce and Data 360 products, which continue to drive analyst interest and support its valuation. Investors are watching for the impact of thin liquidity and the ongoing "Santa Claus rally" as markets reopen on Monday.

**5. Salesforce (CRM) Stock News Today: Agentforce AI Momentum, Analyst Price Targets, and What to Watch Before Monday’s Open**
- Source: ts2.tech | 20251227T044745 | Somewhat-Bullish | Relevance: 100%
- Salesforce (CRM) shares are hovering around $266, driven by momentum in its Agentforce AI platform and capital return program. The company raised its fiscal 2026 guidance based on accelerating AI product demand, with Agentforce + Data 360 ARR reaching nearly $1.4 billion. Investors are now focused on how this AI adoption translates into sustained, paid growth and wider market sentiment ahead of Monday's market open and into the new year.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 6, Lowers: 8)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | BTIG | $335 | $0 | 0% |
| 2025-12-09 | Morgan Stanley | $398 | $405 | -2% |
| 2025-12-08 | Citigroup | $257 | $253 | +2% |
| 2025-12-05 | DA Davidson | $235 | $225 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | BTIG | init | Buy |
| 2025-12-09 | Morgan Stanley | main | Overweight |
| 2025-12-08 | Citigroup | main | Neutral |
| 2025-12-05 | DA Davidson | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($26.11M) |
| Sells | 37 ($11.66M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.8%)
- Blackrock Inc.: 8.7% (-0.5%)
- State Street Corpora: 5.3% (+0.3%)
- JPMORGAN CHASE & CO: 2.8% (+46.5%)
- Geode Capital Manage: 2.2% (+0.6%)

### Key Risks

1. Heavy insider selling: $12M sold (37 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +4%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.24 suggests fair value with growth premium. Quality metrics strong (margin 18%). Balance sheet: $2.2B free cash flow. Analyst sentiment negative (8 target cuts vs 6 raises). Insider buying signal ($26.1M), management confidence. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $253.3B |
| Beta | 1.25 |
| 52W Range | $221.96 - $367.09 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.24 |
| Forward P/E | 20.3 |
| Current P/E | 22.6 |
| YoY Growth | 11.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.7% to 3.5% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.5pp (needs >4.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. AM_20 at 4.5% shows strong absolute momentum above own 20MA. Outperforming sector by 3.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.92), confirming momentum. Volume at 34% of 20MA suggests lack of conviction. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.53% (CS: 87) | Neutral |
| RSI_14 | 65.3 | Neutral |
| MACD Histogram | 0.92 | Bullish |
| vs SMA20 | 1.044x | Above |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 1.034x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $266.10
- **Stop Loss:** $253.94 (4.6% risk)
- **Target:** $290.42 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 90
- **Position Value:** $23,949.00
- **Portfolio %:** 23.95%
- **Risk Dollars:** $1,100.00
- **Risk Per Trade:** 1.10%
- **Modifiers:** L1 110% | L2 100% | Combined 1.10x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-25 (Est: $3.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $2.86 | $3.25 | +13.6% |
| 2025Q3 | $2.78 | $2.91 | +4.7% |
| 2025Q2 | $2.55 | $2.58 | +1.3% |
| 2025Q1 | $2.61 | $2.78 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*